Skip to content
Screener

Lexicon Pharmaceuticals LXRX Q1 2025 earnings

Reported May 13, 2025 · After market close

Revenue$1.3MMiss by $44.7K
EPS-$0.07Beat by $0.03
Revenue estimate$1.3M
EPS estimate-$0.10

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.8M
EPS estimate-$0.06

Financials

Q1 2025

Income statement

See full
Revenue$1.3M+11.7%
Gross profit$1.2M+12.1%
Operating income-$25.7M+43.4%
Net income-$25.3M+47.7%
EPS (diluted)-$0.07+65.0%

Balance sheet

See full
Cash & equivalents$62.9M-34.8%
Total debt$106.3M0.0%
Total equity$123.0M-57.4%
Total assets$297.7M-28.7%

Cash flow

See full
Operating cash flow-$43.8M+20.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$166.58M-71.8%
Enterprise value$209.95M-65.1%
P/S5.3×-250×

Profitability

See full
Gross margin98%+3.0pp
Operating margin-568.6%-274pp
Net margin-568%-274pp

Returns & leverage

See full
Return on equity-86.1%-12.0pp
Debt / equity0.9×+0.5×
Current ratio2.2×-13.4×

Segments

By segment

See full
Reportable Segment$1.3M+11.7%

By product

See full
License-—

FAQ

When did Lexicon Pharmaceuticals report Q1 2025 earnings?
Lexicon Pharmaceuticals (LXRX) reported Q1 2025 earnings on May 13, 2025 after market close.
What were Lexicon Pharmaceuticals's Q1 2025 revenue and EPS?
Lexicon Pharmaceuticals reported revenue of $1.3M and eps of $-0.07 for Q1 2025.
Did Lexicon Pharmaceuticals beat estimates in Q1 2025?
Revenue missed the consensus estimate of $1.3M by $44.7K. EPS beat the consensus estimate of $-0.10 by $0.03.
How did Lexicon Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.7% from $1.1M a year earlier and eps grew 65.0% from $-0.20.
Where can I find Lexicon Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001062822-25-000027) and the 10-Q periodic report (0001062822-25-000029) directly on SEC EDGAR. The filing index links above go to sec.gov.